🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
21.41
+0.02 (0.09%)
Nov 20, 2026, 9:59 AM EST - Market open

Amneal Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 7 analysts polled by S&P Global, Amneal Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $24.29. The average 1-year stock price forecast is 13.45% higher than the current stock price, while the lowest is $20 (-6.59%) and the highest is $28 (+30.78%).

Price Target: $24.29 (+13.45%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$20$24.29$25$28
Change-6.59%+13.45%+16.77%+30.78%

Analyst Ratings

The average analyst rating for Amneal Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy222444
Buy223333
Hold000000
Sell000000
Strong Sell000000
Total445777

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
UBS
UBS
Buy
Reiterates
$25 → $28
BuyReiterates$25 → $28+30.78%Nov 9, 2026
Leerink Partners
Leerink Partners
Buy
Maintains
$23 → $25
BuyMaintains$23 → $25+16.77%Nov 5, 2026
J.P. Morgan
J.P. Morgan
Buy
Maintains
$24 → $25
BuyMaintains$24 → $25+16.77%Nov 4, 2026
Oppenheimer
Oppenheimer
Buy
Maintains
$27
BuyMaintains$27+26.11%Nov 3, 2026
Goldman Sachs
Goldman Sachs
Buy
Maintains
$21 → $24
BuyMaintains$21 → $24+12.10%Oct 29, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
3.21B
from 3.02B
Increased by 6.38%
Revenue Next Year
3.51B
from 3.21B
Increased by 9.21%
EPS This Year
1.06
from 0.83
Increased by 28.04%
EPS Next Year
1.23
from 1.06
Increased by 15.89%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
2.09B2.21B2.39B2.79B3.02B3.21B
Revenue Growth
5.08%5.67%8.20%16.73%8.05%6.38%
Gross Profit
783.95M791.46M852.87M1.02B1.13B1.44B
Gross Margin
37.44%35.78%35.63%36.35%37.38%44.92%
Operating Income
216.60M200.03M260.38M348.36M420.70M701.55M
Net Income
10.62M-129.99M-83.99M-116.89M72.06M83.81M
EPS
----0.831.06
EPS Growth
----43.10%28.04%
Forward PE
5.652.7111.9211.6915.0420.15
Free Cash Flow
----269.93M226.24M
No. Analysts
-----6
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High3.2B
Avg3.2B
Low3.1B

Revenue Growth

Revenue Growth202620272028
High
7.3%
Avg
6.4%
Low
4.2%

EPS Forecast

EPS202620272028
High1.08
Avg1.06
Low1.05

EPS Growth

EPS Growth202620272028
High
30.1%
Avg
28.0%
Low
26.5%